Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
01:59pm, Friday, 08'th Dec 2023
Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease
01:10pm, Friday, 08'th Dec 2023
CNBC's Angelica Peebles reports on the latest news in bioscience.
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
12:03pm, Friday, 08'th Dec 2023
Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing
US approves two gene therapies for sickle cell disease
11:21am, Friday, 08'th Dec 2023
The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
11:19am, Friday, 08'th Dec 2023
Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
Healthcare Gems: 3 Essential Long-Term Stock Picks
06:00pm, Thursday, 07'th Dec 2023
Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world's most pressing issues from heart disease, Alzheim
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
09:10am, Thursday, 07'th Dec 2023
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
05:30am, Thursday, 07'th Dec 2023
Vertex Pharmaceuticals is trying to commercialize its gene therapy exa-cel. Researchers found some disturbing evidence about certain possible side effects.
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
12:47pm, Monday, 04'th Dec 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a
Where Will Vertex Pharmaceuticals Be in 10 Years?
05:30am, Monday, 04'th Dec 2023
Vertex has a solid cystic fibrosis portfolio that generates billions of dollars in annual earnings -- and that's set to continue for the long term. The biotech, expanding into other treatment areas, i
3 No-Brainer Growth Stocks to Buy in December
06:54am, Sunday, 03'rd Dec 2023
Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
05:53am, Sunday, 03'rd Dec 2023
PayPal Holdings has faced multiple challenges, but it's now a bargain with a big comeback opportunity. Vertex Pharmaceuticals could soon have several new blockbuster drugs on the market.
5 Top Stocks to Buy Before 2024
05:00am, Saturday, 02'nd Dec 2023
Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
06:15am, Friday, 01'st Dec 2023
CRISPR and Vertex recently earned approval for a gene-editing treatment, Casgevy. Casgevy shows the potential of CRISPR's platform and should improve its financial results.
3 Biotech Stocks That Could Be Multibaggers in the Making
09:37pm, Thursday, 30'th Nov 2023
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels wit
